Listen to Emma Foreman, Philippe Arnaud and Glenn Myers as they discuss the primary considerations involved in switching from an originator biologic pharmaceutical product to a biosimilar product.
Topic
Improved confidence in the routine use of biosimilars facilitates easier switching and offers more treatment options for Improved confidence in the routine use of biosimilars facilitates easier switching and offers more treatment options for patients and better value for money for hospitals. This webinar aims to educate hospital pharmacists and the wider multidisciplinary team (MDT) on the primary considerations involved in switching from an originator biologic pharmaceutical product to a biosimilar product. In particular, the webinar aims to educate learners on aspects relating to patient safety and pharmacovigilance (PV) requirements, health economics and patient communication.
This 60-minute webinar features insights from expert faculty from across the globe as well as audience questions being answered.
Target audience
This educational activity is designed for hospital-based pharmacists and all other healthcare professionals involved in the management of patients with cancer.
Learning objectives
After watching this webinar, viewers will be able to:
- Recall effective strategies for ensuring patient safety and efficacy when switching between different brands of biologic pharmaceuticals, including pharmacovigilance requirements
- Describe key considerations across a multidisciplinary team when switching from an originator biologic to a biosimilar
- Discuss the potential savings and access to innovation opportunities created by switching from an originator biologic to a biosimilar
